Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

20 de junho de 2014 atualizado por: Boehringer Ingelheim

A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors

Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

38

Estágio

  • Fase 1

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Male or female patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumors, of types historically known to express EGFR and/or HER2, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
  • Age 18 years or older
  • Life expectancy of at least three (3) months
  • Written informed consent given that is consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines
  • Eastern Cooperative Oncology Group (ECOG) performance score 0, 1, or 2
  • Patients must have resolution of prior chemo-, hormone, immuno-, or radiotherapy-related toxicities to CTC Grade < 1
  • Patients have to be recovered from previous surgery
  • Paraffin-embedded tumor material must be accessible for analysis of EGFR and HER2-status.
  • The additional 12 patients that were to be recruited at the MTD also had to fulfill the following criterion: Measurable tumor deposits (RECIST: Response Evaluation Criteria in Solid Tumors) by one or more techniques (X-ray, CT, MRI)

Exclusion Criteria:

  • Active infectious disease
  • Gastrointestinal disorders that might interfere with the absorption of the study drug or chronic diarrhea
  • Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
  • Brain metastases requiring therapy as based on clinical symptoms
  • Impaired cardiac left ventricular function with resting ejection fraction CTC Grade ≥ 1
  • Absolute neutrophil count (ANC) less than 1500 / mm3
  • Platelet count less than 100 000 / mm3
  • Bilirubin greater than 1.5 mg / dl (> 26 μmol / L, SI unit equivalent)
  • Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than three times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
  • Serum creatinine greater than 1.5 mg / dl (> 132 μmol / L, SI (Systeme International) unit equivalent)
  • Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
  • Pregnancy or breast-feeding
  • Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding LHRH agonists, other hormones taken for breast cancer, or bisphosphonates) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study
  • Patients unable to comply with the protocol
  • Active alcohol or drug abuse

RETREATMENT CRITERIA

The patient may be eligible for re-treatment after the previous course finished. The patient will not be eligible if the following criteria are met.

  • Patients with clinical signs of disease progression or if an X-ray, CT or MRI was done and the test showed progressive disease
  • Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course
  • Patients fulfilling any of the Exclusion Criteria as mentioned under exclusion criteria on Day 29 of the previous course
  • Patients not recovered from any dose-limiting toxicity (DLT) 14 days after the last administration of BIBW 2992 in the previous course. Recovery is defined as a return to baseline level or CTC Grade 1, whichever is higher

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: BIBW 2992
escalating doses

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Maximum tolerated dose (MTD)
Prazo: up to 28 months
up to 28 months
Incidence and intensity of Adverse Events (AE) according to Common Terminology Criteria for Adverse Events (CTCAE) associated with increasing doses of BIBW 2992
Prazo: up to 28 months
up to 28 months

Medidas de resultados secundários

Medida de resultado
Prazo
Area under the plasma concentration-time curve (AUC) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Predose plasma concentration (Cpre) for different time points
Prazo: Day 8 and 14
Day 8 and 14
Minimum measured plasma concentration (Cmin) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Maximum measured plasma concentration (Cmax) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Time from dosing to the minimum plasma concentration (tmin) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Time from dosing to the maximum plasma concentration (tmax) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Terminal half-life (t1/2) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Mean residence time after oral administration (MRTpo) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Apparent clearance (CL/F) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Apparent volume of distribution during the terminal phase (Vz/F) for different time points
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Accumulation ratio (RA)
Prazo: up to 384 hours after first drug administration
up to 384 hours after first drug administration
Modulation of biomarker (EGFR, p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki-67, p-27KIP1) in skin biopsies prior to administration of BIBW 2992 and at the end of the first treatment period
Prazo: Baseline and day 14
Baseline and day 14
Modulation of biomarker (EGFR, p-EGFR, HER2, p-MAPK, p-Akt, Ki-67, p-27KIP1) in tumor biopsies prior to administration of BIBW 2992 and at the end of the first treatment period in 6 or more patients treated at the MTD
Prazo: Baseline and day 14
Baseline and day 14
Objective tumor responses
Prazo: every 8 weeks up to 28 months
every 8 weeks up to 28 months
Correlation of EGFR, HER2, estrogen receptor and progesterone receptor immunohistochemical status as based on tumor biopsies or excisions obtained prior to this trial with objective tumor responses
Prazo: up to 28 months
up to 28 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de novembro de 2003

Conclusão Primária (Real)

1 de fevereiro de 2006

Datas de inscrição no estudo

Enviado pela primeira vez

20 de junho de 2014

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de junho de 2014

Primeira postagem (Estimativa)

24 de junho de 2014

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

24 de junho de 2014

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de junho de 2014

Última verificação

1 de junho de 2014

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 1200.1

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em BIBW 2992

3
Se inscrever